Industry Outlook: Down But Not Out - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Industry Outlook: Down But Not Out
The contract services industry may not be as robust in 2009 as it has been in previous years, but it's not as bad as many people think.

Pharmaceutical Technology

Tougher competition

Figure 5
As expected in the soft business environment, competition for new business has intensified. The clearest indicator of this move is the big jump in the number of biopharmaceutical and pharmaceutical respondents claiming that contractors are willing to cut prices to get business: 52% of biopharmaceutical and pharmaceutical respondents indicated that contractors are willing to cut prices, versus 42% last year, and just 34% as recently as 2006 (see Figure 5).

Figure 6
Competition has been intensified by companies' ongoing efforts to consolidate the number of contractors they use. Respondents indicating that they are reducing their vendor base increased slightly, from 27% in 2008 to 31% this year, while the number of respondents with plans to expand their vendor base continued a two-year decline (see Figure 6).

There are still new opportunities, however, for contractors with biopharmaceutical and pharmaceutical companies: nearly half of the survey respondents indicate that they continually identify and test new vendors, while most others are looking for contractors to fill special needs or replace poor performers. Getting on the "short list" of bidders for a project, though, is becoming more difficult according to our survey. Both the number of bidders per project and the share of bids accepted from new vendors declined somewhat over past years.

Figure 7
One trend that seems to have slowed slightly is sourcing from India and China. The share of biopharmaceutical and pharmaceutical respondents indicating that they have no plans to source from India and China rose from 45% last year to 51% in 2009 (see Figure 7). This minor growth does not necessarily imply a lessening of interest in sourcing from Asia, but rather a lull reflecting the overall uncertainty in companies' development programs.

Contractor performance

Figure 8
Clients and contractors continue to view contractor performance differently. Contractor respondents are downright immodest in judging their own performance: more than 90% rated their technical and operational performance as "excellent" or "good," and 88% gave themselves "excellent" or "good" ratings on customer service (see Figure 8).

Clients graded contractor performance on a much tougher curve. Only 57% of biopharmaceutical and pharmaceutical respondents rated contractors' customer service as "excellent" or "good," and only 53% think contractors' project management skills are "excellent" or "good." Contractors fare better on technical and operational performance with 67% of respondents considering them to be "excellent" or "good." On the bright side, only 8–10% of biopharmaceutical and pharmaceutical respondents grade contractors as "poor" or "fair" in these performance categories.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here